期刊
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 15, 期 1, 页码 55-65出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14787210.2017.1251840
关键词
Multi-drug-resistant; Gram-negative pathogens; ESBL; CRE; P. aeruginosa; A. baumanii; carbapenemase
资金
- Pfizer
- MSD
- Gilead
- Teva
- Astellas AstraZeneca
- Bayer
- Basilea
- Novartis
- Shionogi
- Vifor
- Medicines Company
- Tetraphase
Introduction: The isolation of multi-drug-resistant gram-negative (MDRGN) pathogens has progressively increased worldwide and has been associated with important delays in the prescription of an adequate antibiotic treatment, resulting in increased mortality rates. Patient's stratification for MDRGN infections to optimize the prescription of an adequate empiric antimicrobial regimen is crucial.Areas covered: This article covers MDRGN epidemiology, with a specific focus on risk factors for harbouring infections sustained by extended-spectrum-Beta-lactamase (ESBL), carbapenem resistant Enterobacteriacae (CRE), MDR Pseudomonas aeruginosa and MDR Acinetobacter baumanii. Moreover, we will propose an algorithm for the choice of empiric treatment when a MDRGN infection is suspected.Expert commentary: Although in clinical practice, a patient's stratification represents a challenge, whenever a MDRGN pathogen is suspected broad-spectrum, combination empiric treatment should be promptly started, looking for a balance between the prescription of an adequate empiric treatment and the risk of resistance selection.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据